Current Methods for Hyperpolarized [1-13C]pyruvate MRI Human Studies
Authors:
Peder EZ Larson,
Jenna ML Bernard,
James A Bankson,
Nikolaj Bøgh,
Robert A Bok,
Albert P. Chen,
Charles H Cunningham,
Jeremy Gordon,
Jan-Bernd Hövener,
Christoffer Laustsen,
Dirk Mayer,
Mary A McLean,
Franz Schilling,
James Slater,
Jean-Luc Vanderheyden,
Cornelius von Morze,
Daniel B Vigneron,
Duan Xu,
the HP 13C MRI Consensus Group
Abstract:
MRI with hyperpolarized (HP) 13C agents, also known as HP 13C MRI, can measure processes such as localized metabolism that is altered in numerous cancers, liver, heart, kidney diseases, and more. It has been translated into human studies during the past 10 years, with recent rapid growth in studies largely based on increasing availability of hyperpolarized agent preparation methods suitable for us…
▽ More
MRI with hyperpolarized (HP) 13C agents, also known as HP 13C MRI, can measure processes such as localized metabolism that is altered in numerous cancers, liver, heart, kidney diseases, and more. It has been translated into human studies during the past 10 years, with recent rapid growth in studies largely based on increasing availability of hyperpolarized agent preparation methods suitable for use in humans. This paper aims to capture the current successful practices for HP MRI human studies with [1-13C]pyruvate - by far the most commonly used agent, which sits at a key metabolic junction in glycolysis. The paper is divided into four major topic areas: (1) HP 13C-pyruvate preparation, (2) MRI system setup and calibrations, (3) data acquisition and image reconstruction, and (4) data analysis and quantification. In each area, we identified the key components for a successful study, summarized both published studies and current practices, and discuss evidence gaps, strengths, and limitations. This paper is the output of the HP 13C MRI Consensus Group as well as the ISMRM Hyperpolarized Media MR and Hyperpolarized Methods & Equipment study groups. It further aims to provide a comprehensive reference for future consensus building as the field continues to advance human studies with this metabolic imaging modality.
△ Less
Submitted 22 November, 2023; v1 submitted 7 September, 2023;
originally announced September 2023.
